APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Meningococcal Disease Drugs Market Analysis and Forecast 2026-2032

19 December 2025190 pages

Choose your research edition.

Industry ResearchMeningococcal Disease Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Disease Drugs Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Meningococcal Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Disease Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Disease Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Meningococcal Disease Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Meningococcal Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Meningococcal Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Meningococcal Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Meningococcal Disease Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Meningococcal Disease Drugs include Yiling Pharmaceutical, SSY Group Limited, Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Lukang Pharmaceutical Co.,Ltd., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and North China Pharmaceutical Company Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Meningococcal Disease Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Meningococcal Disease Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Meningococcal Disease Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Meningococcal Disease Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Meningococcal Disease Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Meningococcal Disease Drugs sales, projected growth trends, production technology, application and end-user industry.

Meningococcal Disease Drugs Segment by Company

Yiling Pharmaceutical

SSY Group Limited

Apeloa Pharmaceutical Co.,Ltd.

Novartis

Merck Sharp & Dohme

Lukang Pharmaceutical Co.,Ltd.

Shandong Jincheng Pharmaceutical Group Co.,ltd.

Pfizer

North China Pharmaceutical Company Ltd.

Hebei Hejia Pharmaceutical Technology Group Co., Ltd

Harbin Pharmaceutical Group Co.,Ltd.

GlaxoSmithKline

Baiyunshan Pharmaceutical

Sanofi Pasteur

Meningococcal Disease Drugs Segment by Type

Injectable

Oral

Meningococcal Disease Drugs Segment by Application

Hospitals

Drugstores

Others

Meningococcal Disease Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Meningococcal Disease Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Meningococcal Disease Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Disease Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Meningococcal Disease Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injectable Major Manufacturers Table 3. Oral Major Manufacturers Table 4. Global Meningococcal Disease Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospitals Major Manufacturers Table 6. Drugstores Major Manufacturers Table 7. Others Major Manufacturers Table 8. Meningococcal Disease Drugs Industry Trends Table 9. Meningococcal Disease Drugs Industry Drivers Table 10. Meningococcal Disease Drugs Industry Opportunities and Challenges Table 11. Meningococcal Disease Drugs Industry Restraints Table 12. Global Meningococcal Disease Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Meningococcal Disease Drugs Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Meningococcal Disease Drugs Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Meningococcal Disease Drugs Revenue Market Share by Region (2021-2026) Table 16. Global Meningococcal Disease Drugs Revenue Market Share by Region (2027-2032) Table 17. Global Meningococcal Disease Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (Tons) Table 18. Global Meningococcal Disease Drugs Sales by Region (2021-2026) & (Tons) Table 19. Global Meningococcal Disease Drugs Sales by Region (2027-2032) & (Tons) Table 20. Global Meningococcal Disease Drugs Sales Market Share by Region (2021-2026) Table 21. Global Meningococcal Disease Drugs Sales Market Share by Region (2027-2032) Table 22. Global Meningococcal Disease Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Meningococcal Disease Drugs Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Meningococcal Disease Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Meningococcal Disease Drugs Sales Market Share by Manufacturers (2021-2026) Table 26. Global Meningococcal Disease Drugs Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 27. Global Meningococcal Disease Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Meningococcal Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Meningococcal Disease Drugs Manufacturers, Product Type & Application Table 30. Global Meningococcal Disease Drugs Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Meningococcal Disease Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Meningococcal Disease Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Meningococcal Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Meningococcal Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Meningococcal Disease Drugs Revenue Market Share by Type (2021-2026) Table 37. Global Meningococcal Disease Drugs Revenue Market Share by Type (2027-2032) Table 38. Global Meningococcal Disease Drugs Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 39. Global Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 40. Global Meningococcal Disease Drugs Sales by Type (2027-2032) & (Tons) Table 41. Global Meningococcal Disease Drugs Sales Market Share by Type (2021-2026) Table 42. Global Meningococcal Disease Drugs Sales Market Share by Type (2027-2032) Table 43. Global Meningococcal Disease Drugs Price by Type (2021-2026) & (US$/Ton) Table 44. Global Meningococcal Disease Drugs Price by Type (2027-2032) & (US$/Ton) Table 45. Global Meningococcal Disease Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Meningococcal Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Meningococcal Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Meningococcal Disease Drugs Revenue Market Share by Application (2021-2026) Table 49. Global Meningococcal Disease Drugs Revenue Market Share by Application (2027-2032) Table 50. Global Meningococcal Disease Drugs Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 51. Global Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 52. Global Meningococcal Disease Drugs Sales by Application (2027-2032) & (Tons) Table 53. Global Meningococcal Disease Drugs Sales Market Share by Application (2021-2026) Table 54. Global Meningococcal Disease Drugs Sales Market Share by Application (2027-2032) Table 55. Global Meningococcal Disease Drugs Price by Application (2021-2026) & (US$/Ton) Table 56. Global Meningococcal Disease Drugs Price by Application (2027-2032) & (US$/Ton) Table 57. Yiling Pharmaceutical Company Information Table 58. Yiling Pharmaceutical Business Overview Table 59. Yiling Pharmaceutical Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 60. Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio Table 61. Yiling Pharmaceutical Recent Development Table 62. SSY Group Limited Company Information Table 63. SSY Group Limited Business Overview Table 64. SSY Group Limited Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 65. SSY Group Limited Meningococcal Disease Drugs Product Portfolio Table 66. SSY Group Limited Recent Development Table 67. Apeloa Pharmaceutical Co.,Ltd. Company Information Table 68. Apeloa Pharmaceutical Co.,Ltd. Business Overview Table 69. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 70. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 71. Apeloa Pharmaceutical Co.,Ltd. Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 75. Novartis Meningococcal Disease Drugs Product Portfolio Table 76. Novartis Recent Development Table 77. Merck Sharp & Dohme Company Information Table 78. Merck Sharp & Dohme Business Overview Table 79. Merck Sharp & Dohme Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 80. Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio Table 81. Merck Sharp & Dohme Recent Development Table 82. Lukang Pharmaceutical Co.,Ltd. Company Information Table 83. Lukang Pharmaceutical Co.,Ltd. Business Overview Table 84. Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 85. Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 86. Lukang Pharmaceutical Co.,Ltd. Recent Development Table 87. Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information Table 88. Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview Table 89. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 90. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio Table 91. Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 95. Pfizer Meningococcal Disease Drugs Product Portfolio Table 96. Pfizer Recent Development Table 97. North China Pharmaceutical Company Ltd. Company Information Table 98. North China Pharmaceutical Company Ltd. Business Overview Table 99. North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 100. North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio Table 101. North China Pharmaceutical Company Ltd. Recent Development Table 102. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information Table 103. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview Table 104. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 105. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio Table 106. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development Table 107. Harbin Pharmaceutical Group Co.,Ltd. Company Information Table 108. Harbin Pharmaceutical Group Co.,Ltd. Business Overview Table 109. Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 110. Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 111. Harbin Pharmaceutical Group Co.,Ltd. Recent Development Table 112. GlaxoSmithKline Company Information Table 113. GlaxoSmithKline Business Overview Table 114. GlaxoSmithKline Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 115. GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio Table 116. GlaxoSmithKline Recent Development Table 117. Baiyunshan Pharmaceutical Company Information Table 118. Baiyunshan Pharmaceutical Business Overview Table 119. Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 120. Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio Table 121. Baiyunshan Pharmaceutical Recent Development Table 122. Sanofi Pasteur Company Information Table 123. Sanofi Pasteur Business Overview Table 124. Sanofi Pasteur Meningococcal Disease Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 125. Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio Table 126. Sanofi Pasteur Recent Development Table 127. North America Meningococcal Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Meningococcal Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 130. North America Meningococcal Disease Drugs Sales by Type (2027-2032) & (Tons) Table 131. North America Meningococcal Disease Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 132. North America Meningococcal Disease Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 133. North America Meningococcal Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 134. North America Meningococcal Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 135. North America Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 136. North America Meningococcal Disease Drugs Sales by Application (2027-2032) & (Tons) Table 137. North America Meningococcal Disease Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 138. North America Meningococcal Disease Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 139. North America Meningococcal Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Meningococcal Disease Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. North America Meningococcal Disease Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. North America Meningococcal Disease Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 143. North America Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 144. North America Meningococcal Disease Drugs Sales by Country (2027-2032) & (Tons) Table 145. North America Meningococcal Disease Drugs Sales Price by Country (2021-2026) & (US$/Ton) Table 146. North America Meningococcal Disease Drugs Sales Price by Country (2027-2032) & (US$/Ton) Table 147. United States Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 148. Canada Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 149. Europe Meningococcal Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 150. Europe Meningococcal Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 151. Europe Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 152. Europe Meningococcal Disease Drugs Sales by Type (2027-2032) & (Tons) Table 153. Europe Meningococcal Disease Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 154. Europe Meningococcal Disease Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 155. Europe Meningococcal Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 156. Europe Meningococcal Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 157. Europe Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 158. Europe Meningococcal Disease Drugs Sales by Application (2027-2032) & (Tons) Table 159. Europe Meningococcal Disease Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 160. Europe Meningococcal Disease Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 161. Europe Meningococcal Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Europe Meningococcal Disease Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Europe Meningococcal Disease Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Europe Meningococcal Disease Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 165. Europe Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 166. Europe Meningococcal Disease Drugs Sales by Country (2027-2032) & (Tons) Table 167. Europe Meningococcal Disease Drugs Sales Price by Country (2021-2026) & (US$/Ton) Table 168. Europe Meningococcal Disease Drugs Sales Price by Country (2027-2032) & (US$/Ton) Table 169. Germany Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 170. France Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 171. U.K. Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 172. Italy Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 173. Netherlands Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 174. Nordic Countries Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 175. China Meningococcal Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 176. China Meningococcal Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 177. China Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 178. China Meningococcal Disease Drugs Sales by Type (2027-2032) & (Tons) Table 179. China Meningococcal Disease Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 180. China Meningococcal Disease Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 181. China Meningococcal Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 182. China Meningococcal Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 183. China Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 184. China Meningococcal Disease Drugs Sales by Application (2027-2032) & (Tons) Table 185. China Meningococcal Disease Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 186. China Meningococcal Disease Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 187. Asia Meningococcal Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 188. Asia Meningococcal Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 189. Asia Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 190. Asia Meningococcal Disease Drugs Sales by Type (2027-2032) & (Tons) Table 191. Asia Meningococcal Disease Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 192. Asia Meningococcal Disease Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 193. Asia Meningococcal Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 194. Asia Meningococcal Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 195. Asia Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 196. Asia Meningococcal Disease Drugs Sales by Application (2027-2032) & (Tons) Table 197. Asia Meningococcal Disease Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 198. Asia Meningococcal Disease Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 199. Asia Meningococcal Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. Asia Meningococcal Disease Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. Asia Meningococcal Disease Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. Asia Meningococcal Disease Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 203. Asia Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 204. Asia Meningococcal Disease Drugs Sales by Country (2027-2032) & (Tons) Table 205. Asia Meningococcal Disease Drugs Sales Price by Country (2021-2026) & (US$/Ton) Table 206. Asia Meningococcal Disease Drugs Sales Price by Country (2027-2032) & (US$/Ton) Table 207. Japan Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 208. South Korea Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 209. India Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 210. Australia Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 211. China Taiwan Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 212. Southeast Asia Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 213. SAMEA Meningococcal Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 214. SAMEA Meningococcal Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 215. SAMEA Meningococcal Disease Drugs Sales by Type (2021-2026) & (Tons) Table 216. SAMEA Meningococcal Disease Drugs Sales by Type (2027-2032) & (Tons) Table 217. SAMEA Meningococcal Disease Drugs Sales Price by Type (2021-2026) & (US$/Ton) Table 218. SAMEA Meningococcal Disease Drugs Sales Price by Type (2027-2032) & (US$/Ton) Table 219. SAMEA Meningococcal Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 220. SAMEA Meningococcal Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 221. SAMEA Meningococcal Disease Drugs Sales by Application (2021-2026) & (Tons) Table 222. SAMEA Meningococcal Disease Drugs Sales by Application (2027-2032) & (Tons) Table 223. SAMEA Meningococcal Disease Drugs Sales Price by Application (2021-2026) & (US$/Ton) Table 224. SAMEA Meningococcal Disease Drugs Sales Price by Application (2027-2032) & (US$/Ton) Table 225. SAMEA Meningococcal Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 226. SAMEA Meningococcal Disease Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 227. SAMEA Meningococcal Disease Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 228. SAMEA Meningococcal Disease Drugs Sales by Country (2021 VS 2025 VS 2032) & (Tons) Table 229. SAMEA Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 230. SAMEA Meningococcal Disease Drugs Sales by Country (2027-2032) & (Tons) Table 231. SAMEA Meningococcal Disease Drugs Sales Price by Country (2021-2026) & (US$/Ton) Table 232. SAMEA Meningococcal Disease Drugs Sales Price by Country (2027-2032) & (US$/Ton) Table 233. Brazil Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 234. Argentina Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 235. Chile Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 236. Colombia Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 237. Peru Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 238. Saudi Arabia Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 239. Israel Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 240. UAE Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 241. Turkey Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 242. Iran Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 243. Egypt Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Table 244. Key Raw Materials Table 245. Raw Materials Key Suppliers Table 246. Meningococcal Disease Drugs Distributors List Table 247. Meningococcal Disease Drugs Customers List Table 248. Research Programs/Design for This Report Table 249. Authors List of This Report Table 250. Secondary Sources Table 251. Primary Sources List of Figures Figure 1. Meningococcal Disease Drugs Image Figure 2. Global Meningococcal Disease Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Disease Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injectable Image Figure 5. Oral Image Figure 6. Global Meningococcal Disease Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Meningococcal Disease Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospitals Image Figure 9. Drugstores Image Figure 10. Others Image Figure 11. Global Meningococcal Disease Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Meningococcal Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 13. Global Meningococcal Disease Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Meningococcal Disease Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Meningococcal Disease Drugs Revenue Market Share by Region (2021-2032) Figure 16. Global Meningococcal Disease Drugs Sales (2021-2032) & (Tons) Figure 17. Global Meningococcal Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 18. Global Meningococcal Disease Drugs Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Meningococcal Disease Drugs Sales YoY (2021-2032) & (Tons) Figure 20. Europe Meningococcal Disease Drugs Sales YoY (2021-2032) & (Tons) Figure 21. China Meningococcal Disease Drugs Sales YoY (2021-2032) & (Tons) Figure 22. Asia (Excluding China) Meningococcal Disease Drugs Sales YoY (2021-2032) & (Tons) Figure 23. South America, Middle East and Africa Meningococcal Disease Drugs Sales YoY (2021-2032) & (Tons) Figure 24. Global Meningococcal Disease Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Meningococcal Disease Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Meningococcal Disease Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Meningococcal Disease Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Meningococcal Disease Drugs Revenue Market Share by Type (2021-2032) Figure 30. Global Meningococcal Disease Drugs Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 31. Global Meningococcal Disease Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Meningococcal Disease Drugs Sales Market Share by Type (2021-2032) Figure 33. Global Meningococcal Disease Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Meningococcal Disease Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Meningococcal Disease Drugs Revenue Market Share by Application (2021-2032) Figure 36. Global Meningococcal Disease Drugs Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 37. Global Meningococcal Disease Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Meningococcal Disease Drugs Sales Market Share by Application (2021-2032) Figure 39. North America Meningococcal Disease Drugs Revenue Share by Type (2021-2032) Figure 40. North America Meningococcal Disease Drugs Sales Share by Type (2021-2032) Figure 41. North America Meningococcal Disease Drugs Revenue Share by Application (2021-2032) Figure 42. North America Meningococcal Disease Drugs Sales Share by Application (2021-2032) Figure 43. North America Meningococcal Disease Drugs Revenue Share by Country (2021-2032) Figure 44. North America Meningococcal Disease Drugs Sales Share by Country (2021-2032) Figure 45. Europe Meningococcal Disease Drugs Revenue Share by Type (2021-2032) Figure 46. Europe Meningococcal Disease Drugs Sales Share by Type (2021-2032) Figure 47. Europe Meningococcal Disease Drugs Revenue Share by Application (2021-2032) Figure 48. Europe Meningococcal Disease Drugs Sales Share by Application (2021-2032) Figure 49. Europe Meningococcal Disease Drugs Revenue Share by Country (2021-2032) Figure 50. Europe Meningococcal Disease Drugs Sales Share by Country (2021-2032) Figure 51. China Meningococcal Disease Drugs Revenue Share by Type (2021-2032) Figure 52. China Meningococcal Disease Drugs Sales Share by Type (2021-2032) Figure 53. China Meningococcal Disease Drugs Revenue Share by Application (2021-2032) Figure 54. China Meningococcal Disease Drugs Sales Share by Application (2021-2032) Figure 55. Asia Meningococcal Disease Drugs Revenue Share by Type (2021-2032) Figure 56. Asia Meningococcal Disease Drugs Sales Share by Type (2021-2032) Figure 57. Asia Meningococcal Disease Drugs Revenue Share by Application (2021-2032) Figure 58. Asia Meningococcal Disease Drugs Sales Share by Application (2021-2032) Figure 59. Asia Meningococcal Disease Drugs Revenue Share by Country (2021-2032) Figure 60. Asia Meningococcal Disease Drugs Sales Share by Country (2021-2032) Figure 61. SAMEA Meningococcal Disease Drugs Revenue Share by Type (2021-2032) Figure 62. SAMEA Meningococcal Disease Drugs Sales Share by Type (2021-2032) Figure 63. SAMEA Meningococcal Disease Drugs Revenue Share by Application (2021-2032) Figure 64. SAMEA Meningococcal Disease Drugs Sales Share by Application (2021-2032) Figure 65. SAMEA Meningococcal Disease Drugs Revenue Share by Country (2021-2032) Figure 66. SAMEA Meningococcal Disease Drugs Sales Share by Country (2021-2032) Figure 67. Meningococcal Disease Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Meningococcal Disease Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Injectable
  • Oral
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Yiling Pharmaceutical
  • SSY Group Limited
  • Apeloa Pharmaceutical Co.,Ltd.
  • Novartis
  • Merck Sharp & Dohme
  • Lukang Pharmaceutical Co.,Ltd.
  • Shandong Jincheng Pharmaceutical Group Co.,ltd.
  • Pfizer
  • North China Pharmaceutical Company Ltd.
  • Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  • Harbin Pharmaceutical Group Co.,Ltd.
  • GlaxoSmithKline
  • Baiyunshan Pharmaceutical
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Meningococcal Disease Drugs Market by Type
  3. 1.2.1 Global Meningococcal Disease Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injectable
  5. 1.2.3 Oral
  6. 1.3 Meningococcal Disease Drugs Market by Application
  7. 1.3.1 Global Meningococcal Disease Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals
  9. 1.3.3 Drugstores
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Meningococcal Disease Drugs Market Dynamics
  1. 2.1 Meningococcal Disease Drugs Industry Trends
  2. 2.2 Meningococcal Disease Drugs Industry Drivers
  3. 2.3 Meningococcal Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Meningococcal Disease Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Meningococcal Disease Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Meningococcal Disease Drugs Revenue by Region
  3. 3.2.1 Global Meningococcal Disease Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Meningococcal Disease Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Meningococcal Disease Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Meningococcal Disease Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Meningococcal Disease Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Meningococcal Disease Drugs Sales by Region
  9. 3.4.1 Global Meningococcal Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Meningococcal Disease Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Meningococcal Disease Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Meningococcal Disease Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Meningococcal Disease Drugs Revenue by Manufacturers
  2. 4.1.1 Global Meningococcal Disease Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Meningococcal Disease Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Meningococcal Disease Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Meningococcal Disease Drugs Sales by Manufacturers
  6. 4.2.1 Global Meningococcal Disease Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Meningococcal Disease Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Meningococcal Disease Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Meningococcal Disease Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Meningococcal Disease Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Meningococcal Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Meningococcal Disease Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Meningococcal Disease Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Meningococcal Disease Drugs Market CR5 and HHI
  16. 4.8.2 2025 Meningococcal Disease Drugs Tier 1, Tier 2, and Tier 3
5 Meningococcal Disease Drugs Market by Type
  1. 5.1 Global Meningococcal Disease Drugs Revenue by Type
  2. 5.1.1 Global Meningococcal Disease Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Meningococcal Disease Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Meningococcal Disease Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Meningococcal Disease Drugs Sales by Type
  6. 5.2.1 Global Meningococcal Disease Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Meningococcal Disease Drugs Sales by Type (2021-2032) & (Tons)
  8. 5.2.3 Global Meningococcal Disease Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Meningococcal Disease Drugs Price by Type
6 Meningococcal Disease Drugs Market by Application
  1. 6.1 Global Meningococcal Disease Drugs Revenue by Application
  2. 6.1.1 Global Meningococcal Disease Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Meningococcal Disease Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Meningococcal Disease Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Meningococcal Disease Drugs Sales by Application
  6. 6.2.1 Global Meningococcal Disease Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Meningococcal Disease Drugs Sales by Application (2021-2032) & (Tons)
  8. 6.2.3 Global Meningococcal Disease Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Meningococcal Disease Drugs Price by Application
7 Company Profiles
  1. 7.1 Yiling Pharmaceutical
  2. 7.1.1 Yiling Pharmaceutical Company Information
  3. 7.1.2 Yiling Pharmaceutical Business Overview
  4. 7.1.3 Yiling Pharmaceutical Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio
  6. 7.1.5 Yiling Pharmaceutical Recent Developments
  7. 7.2 SSY Group Limited
  8. 7.2.1 SSY Group Limited Company Information
  9. 7.2.2 SSY Group Limited Business Overview
  10. 7.2.3 SSY Group Limited Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 SSY Group Limited Meningococcal Disease Drugs Product Portfolio
  12. 7.2.5 SSY Group Limited Recent Developments
  13. 7.3 Apeloa Pharmaceutical Co.,Ltd.
  14. 7.3.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
  15. 7.3.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
  16. 7.3.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  18. 7.3.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Meningococcal Disease Drugs Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Merck Sharp & Dohme
  26. 7.5.1 Merck Sharp & Dohme Company Information
  27. 7.5.2 Merck Sharp & Dohme Business Overview
  28. 7.5.3 Merck Sharp & Dohme Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio
  30. 7.5.5 Merck Sharp & Dohme Recent Developments
  31. 7.6 Lukang Pharmaceutical Co.,Ltd.
  32. 7.6.1 Lukang Pharmaceutical Co.,Ltd. Company Information
  33. 7.6.2 Lukang Pharmaceutical Co.,Ltd. Business Overview
  34. 7.6.3 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  36. 7.6.5 Lukang Pharmaceutical Co.,Ltd. Recent Developments
  37. 7.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
  38. 7.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
  39. 7.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
  40. 7.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio
  42. 7.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Meningococcal Disease Drugs Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 North China Pharmaceutical Company Ltd.
  50. 7.9.1 North China Pharmaceutical Company Ltd. Company Information
  51. 7.9.2 North China Pharmaceutical Company Ltd. Business Overview
  52. 7.9.3 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio
  54. 7.9.5 North China Pharmaceutical Company Ltd. Recent Developments
  55. 7.10 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  56. 7.10.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
  57. 7.10.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
  58. 7.10.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio
  60. 7.10.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
  61. 7.11 Harbin Pharmaceutical Group Co.,Ltd.
  62. 7.11.1 Harbin Pharmaceutical Group Co.,Ltd. Company Information
  63. 7.11.2 Harbin Pharmaceutical Group Co.,Ltd. Business Overview
  64. 7.11.3 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  66. 7.11.5 Harbin Pharmaceutical Group Co.,Ltd. Recent Developments
  67. 7.12 GlaxoSmithKline
  68. 7.12.1 GlaxoSmithKline Company Information
  69. 7.12.2 GlaxoSmithKline Business Overview
  70. 7.12.3 GlaxoSmithKline Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio
  72. 7.12.5 GlaxoSmithKline Recent Developments
  73. 7.13 Baiyunshan Pharmaceutical
  74. 7.13.1 Baiyunshan Pharmaceutical Company Information
  75. 7.13.2 Baiyunshan Pharmaceutical Business Overview
  76. 7.13.3 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio
  78. 7.13.5 Baiyunshan Pharmaceutical Recent Developments
  79. 7.14 Sanofi Pasteur
  80. 7.14.1 Sanofi Pasteur Company Information
  81. 7.14.2 Sanofi Pasteur Business Overview
  82. 7.14.3 Sanofi Pasteur Meningococcal Disease Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio
  84. 7.14.5 Sanofi Pasteur Recent Developments
8 North America
  1. 8.1 North America Meningococcal Disease Drugs Market Size by Type
  2. 8.1.1 North America Meningococcal Disease Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Meningococcal Disease Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Meningococcal Disease Drugs Price by Type (2021-2032)
  5. 8.2 North America Meningococcal Disease Drugs Market Size by Application
  6. 8.2.1 North America Meningococcal Disease Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Meningococcal Disease Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Meningococcal Disease Drugs Price by Application (2021-2032)
  9. 8.3 North America Meningococcal Disease Drugs Market Size by Country
  10. 8.3.1 North America Meningococcal Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Meningococcal Disease Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Meningococcal Disease Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Meningococcal Disease Drugs Market Size by Type
  2. 9.1.1 Europe Meningococcal Disease Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Meningococcal Disease Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Meningococcal Disease Drugs Price by Type (2021-2032)
  5. 9.2 Europe Meningococcal Disease Drugs Market Size by Application
  6. 9.2.1 Europe Meningococcal Disease Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Meningococcal Disease Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Meningococcal Disease Drugs Price by Application (2021-2032)
  9. 9.3 Europe Meningococcal Disease Drugs Market Size by Country
  10. 9.3.1 Europe Meningococcal Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Meningococcal Disease Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Meningococcal Disease Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Meningococcal Disease Drugs Market Size by Type
  2. 10.1.1 China Meningococcal Disease Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Meningococcal Disease Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Meningococcal Disease Drugs Price by Type (2021-2032)
  5. 10.2 China Meningococcal Disease Drugs Market Size by Application
  6. 10.2.1 China Meningococcal Disease Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Meningococcal Disease Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Meningococcal Disease Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Meningococcal Disease Drugs Market Size by Type
  2. 11.1.1 Asia Meningococcal Disease Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Meningococcal Disease Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Meningococcal Disease Drugs Price by Type (2021-2032)
  5. 11.2 Asia Meningococcal Disease Drugs Market Size by Application
  6. 11.2.1 Asia Meningococcal Disease Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Meningococcal Disease Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Meningococcal Disease Drugs Price by Application (2021-2032)
  9. 11.3 Asia Meningococcal Disease Drugs Market Size by Country
  10. 11.3.1 Asia Meningococcal Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Meningococcal Disease Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Meningococcal Disease Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Meningococcal Disease Drugs Market Size by Type
  2. 12.1.1 SAMEA Meningococcal Disease Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Meningococcal Disease Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Meningococcal Disease Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Meningococcal Disease Drugs Market Size by Application
  6. 12.2.1 SAMEA Meningococcal Disease Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Meningococcal Disease Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Meningococcal Disease Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Meningococcal Disease Drugs Market Size by Country
  10. 12.3.1 SAMEA Meningococcal Disease Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Meningococcal Disease Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Meningococcal Disease Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Meningococcal Disease Drugs Value Chain Analysis
  2. 13.1.1 Meningococcal Disease Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Meningococcal Disease Drugs Production Mode & Process
  6. 13.2 Meningococcal Disease Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Meningococcal Disease Drugs Distributors
  9. 13.2.3 Meningococcal Disease Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst